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The present study was conducted to evaluate the efficacy and safety of a combination regimen of capecitabine plus irinotecan in
patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received
oral capecitabine 1000mgm
 2 twice daily from day 1 to 14 and intravenous irinotecan 100mgm
 2 on days 1 and 8, based on a
3-week cycle. Forty-one patients were enrolled in the current study, among whom 38 were assessable for efficacy and 40 assessable
for toxicity. Three complete responses and 16 partial responses were confirmed, giving an overall response rate of 46.3%. At a
median follow-up of 269 days, the median time to progression and overall survival were 5.1 and 8.6 months, respectively. Grade 3/4
neutropenia occurred in four patients and grade 3 febrile neutropenia was observed in two patients. Grade 3 diarrhoea and grade 2
hand–foot syndrome occurred in six patients and eight patients, respectively. The combination of capecitabine and irinotecan was
found to be well tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as one of
first-line treatment options for advanced gastric cancer.
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Despite a declining incidence in many developed countries, gastric
cancer remains the second most common cancer-related death in
the world (Pisani et al, 1999). Although the prognosis for advanced
gastric cancer is poor, combination chemotherapy has improved
the quality of life and overall survival compared with the best
supportive care in several randomised studies (Murad et al, 1993;
Glimelius et al, 1994; Pyrhonen et al, 1995). Among the various
active chemotherapeutic agents, cisplatin-based combination
chemotherapy has been most commonly used with a high response
rate of 48–56% (Kim et al, 1993; Boku et al, 1999; Roth et al, 2000).
Yet, notwithstanding its active anticancer effect in the treatment
of advanced gastric cancer, cisplatin also induces nausea and
vomiting in most patients (Boku et al, 1999; Roth et al, 2000).
Plus, despite the development of new antiemetic agents, nausea
and vomiting are still the main treatment-interrupting complica-
tions.
As such, oral fluoropyrimidine capecitabine (Xeloda
s; Hoffmann-
La Roche Inc., Nutley, NJ, USA) was rationally designed to
preferentially generate 5-FU in tumour tissue and mimic
continuous-infusion 5-FU. This tumour selectivity is achieved
through exploiting the significantly higher activity of thymidine
phosphorylase in many tumour tissues compared with healthy
tissue (Miwa et al, 1998; Schuller et al, 2000). In addition,
capecitabine has also exhibited antitumour activity with tolerable
safety profiles when given as a monotherapy or in combination
with cisplatin in patients with various other solid tumours as well
as advanced gastric cancer (Kim et al, 2002; Ahn et al, 2003;
Koizumi et al, 2003).
Meanwhile, irinotecan is a semisynthetic, water-soluble
derivative of the plant alkaloid camptothecin. After conversion
to its active metabolite, SN-38, irinotecan acts by inhibiting the
enzyme DNA-topoisomerase I. Irinotecan has also shown promis-
ing activity in advanced gastric cancer as a single agent or
combined with other agents (Boku et al, 1999; Ajani et al, 2001;
Bugat, 2003).
The combination of capecitabine plus irinotecan has
already shown synergistic antitumour activity in preclinical
and clinical studies (Cassata et al, 2001; Jordan et al, 2002),
where preclinical evidence indicated that irinotecan up-
regulates thymidine phosphorylase expression (Jordan et al,
2002), possibly providing the basis for the synergistic anti-
tumour activity of the capecitabine and irinotecan combina-
tion. Furthermore, capecitabine and irinotecan have distinct action
mechanisms and only partially overlapping adverse event
profiles.
Although several studies have shown the efficacy and safety of
capecitabine and irinotecan for advanced colorectal cancer (Tewes
et al, 2003; Bajetta et al, 2004; Borner et al, 2005; Kim et al, 2005;
Rea et al, 2005), no results have yet been reported for advanced
gastric cancer. Accordingly, the current phase II study was
conducted to evaluate the efficacy and safety of a combination
regimen of capecitabine plus irinotecan in patients with advanced
gastric cancer.
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sPATIENTS AND METHODS
Eligibility
All the patients involved in the current study had histologically
confirmed metastatic or recurrent gastric adenocarcinoma with at
least one unidimensionally measurable lesion. The patients were
18–75 years of age with a performance status of 0–2 on the
Eastern Cooperative Oncology Group (ECOG) scale. Also, adequate
haematological (absolute neutrophil count X1.5 10
9l
 l, platelet
count X100 10
9l
 l, and haemoglobin X9gdl
 1), renal (serum
creatinine p1.5mgdl
 1 and creatinine clearance X50mlmin
 1),
and hepatic (total bilirubin p1.5mgdl
 1 and serum transaminase
level p2.5 times the upper normal limit (UNL) or p5 times the
UNL in cases of hepatic metastases) functions were also required.
Patients were ineligible if they had previously received palliative
chemotherapy or radiation therapy, or had other severe medical
illnesses, CNS metastasis, or another active malignancy. The
protocol was approved by the institutional review board of each
centre, and written informed consent obtained from all patients
before enrolment. The ethical opinion was also considered by the
institutional review board.
Study treatment
All the treatments were administered on an outpatient basis.
Capecitabine 1000mgm
 2 b.i.d. with pyridoxine 100mg t.i.d. was
given on days 1–14 followed by a 7-day rest period. The
capecitabine was supplied as film-coated tablets at two dose
strengths, 150 and 500mg, whereas the irinotecan 100mgm
 2 was
administered through a 90-min intravenous infusion on days 1 and
8, based on a 3-week cycle. All patients received 5-HT3 inhibitors
for emesis prophylaxis. Treatment was continued until disease
progression, patient refusal, or an unacceptable toxicity with a
maximum of nine cycles.
Dose modification
The next course of treatment only began when the neutrophil
count was X1.5 10
9l
 l, the platelet count was X75 10
9l
 l, and
any other treatment-related toxicities were less than or equal to
grade 1; otherwise, treatment was withheld for up to 2 weeks. If
adverse events did not improve to grade 0 or 1 after 3 weeks, the
patients were excluded from the study.
The capecitabine treatment within a particular cycle was
withheld in the presence of repeated grade 2 or any grade X3
haematological or non-haematological toxicity. The capecitabine
treatment was then resumed at a 25% dose reduction after a
resolution of the toxicity to grade 0–1. An additional 25% dose
reduction was also applied in the case of repeated grade X3
toxicity. For grade 2–3 hand–foot syndrome (HFS), the capeci-
tabine treatment was withheld until a resolution to less than or
equal to grade 1, then restarted with a 25% dose reduction.
The irinotecan treatment on day 8 was omitted in the presence
of grade X3 haematological or non-haematological toxicity on the
day scheduled for the irinotecan administration, and the patient
then re-evaluated weekly until regressing to less than or equal to
grade 1. Missed doses of irinotecan were not made up. The
following cycle of treatment was reduced by 25% in the case of
repeated grade 2 or any grade 3 toxicity and reduced by 50% in
the case of repeated grade 3 or any grade 4 toxicity during the
preceding cycle.
Study assessments
A screening assessment, including the medical history, a physical
examination, ECG, chest X-ray, and tumour assessment, was
conducted within 2 weeks before starting the treatment. Further
assessments conducted within 7 days before starting the treatment
included vital signs, an ECOG performance status, and laboratory
tests (haematology, blood chemistry, and urinalysis). Complete
blood counts were performed before and on day 8 of each cycle,
and biochemical tests performed before each cycle. The tumours
were measured by computed tomography (CT) scans every three
cycles until the tumour progressed. The tumour responses were
classified according to the response evaluation criteria in solid
tumours (RECIST) guidelines (Therasse et al, 2000) complete
response (CR), the disappearance of all target lesions; partial
response (PR), a decrease of at least 30% in the sum of the longest
diameters of the target lesions; progressive disease (PD), an
increase of at least 20% in the sum of the longest diameters of the
target lesions or the appearance of one or more new lesions; stable
disease (SD), neither sufficient shrinkage to qualify for PR nor
a sufficient increase to qualify for PD. Complete response or PR
patients were required to undergo a confirmatory disease
assessment at least 4 weeks later. Adverse events were graded
according to the National Cancer Institute Common Toxicity
Criteria for Adverse Events (NCI-CTCAE) version 3.0; HFS was
graded 1–3, as defined in previous capecitabine clinical studies
(Blum et al, 1999).
Statistical analysis
The current trial was designed to detect a response rate of 40% as
compared to a minimal, clinically meaningful response rate of
20%. Plus, the current trial used a two-stage optimal MiniMax
design, as proposed by Simon, (1989), with an 80% power to accept
the hypothesis and 5% significance to reject the hypothesis
(Simon, 1989). Allowing for a follow-up loss rate of 10%, the total
sample size was 37 patients with a measurable disease. The
duration of response, time to progression (TTP), and survival
analysis were estimated using the Kaplan–Meier method. The
duration of response was defined as the interval from the onset of
CR or PR until evidence of PD was found. Meanwhile, the time to
progression was calculated from the initiation of chemotherapy to
the date of disease progression, and the overall survival measured
from the initiation of chemotherapy to the date of the last follow-
up or death. The statistical data were obtained using an SPSS
software package (SPSS 11.5 Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
Between July 2004 and March 2005, 41 patients were enrolled in the
present study from two centres. The characteristics of the patients
are summarised in Table 1. The median age was 59.0 (range: 25–
74) years, and there were 30 men and 11 women. Most of the
patients (92.7%) had a good performance status (ECOG 0 or 1).
Twenty-nine (70.7%) patients were suffering from a metastatic
disease, whereas 12 patients had a recurrent disease after surgical
resection (total or subtotal gastrectomy) of the primary tumour.
Distal lymph nodes and the liver were the most common sites of
the metastases.
Efficacy
Thirty-eight of the 41 patients (92.7%) were assessable for
response, with the remaining three being lost to follow-up or
patient refusal. All efficacy data are reported using the intention-
to-treat patient population. Three cases of CR and 16 cases of PR
were confirmed, giving an overall response rate of 46.3% (95% CI:
30.4–62.3%). The response characteristics are shown in Table 2.
The median duration of response in the 19 responding patients
was 4.6 months (95% CI: 3.3–5.9 months), whereas the median
TTP for all patients was 5.1 months (95% CI: 3.9–6.3 months) at a
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Twenty-seven patients had died at the time of the present
evaluation. The median overall survival was 8.6 months (95% CI:
6.1–11.1 months) with a 1-year survival rate of 32.6% (Figure 1).
Toxicity
The haematological and non-haematological toxicities that oc-
curred during the current study are summarised in Table 3. A total
of 160 cycles (median 3, range 1–9 cycles) were administrated in
40 patients assessable for toxicity. The most severe haematological
adverse event was neutropenia, which occurred with a grade 3/4
intensity in four patients (10.0%) in seven cycles (4.4%). Plus,
febrile neutropenia was observed in two patients (5.0%). All cases
were successfully treated with antibiotics and G-CSF, and there
were no treatment-related deaths during this study. The most
common non-haematological toxicity was nausea (grade 1/2,
80.0%). Grade 3 diarrhoea occurred in six patients (15.0%) and
grade 2 HFS, a complication of capecitabine, occurred in four
patients (10.0%). Yet, no grade 4 non-haematological toxicity was
observed. Overall, 10 (25.0%) patients and 27 (16.9%) cycles
required a dose reduction of irinotecan on day 1, whereas dose
omissions of irinotecan on day 8 were needed in 18 (11.3%) cycles.
Also, a total of eight (5.0%) cycles were delayed. The most
common reasons for the dose modification of irinotecan were
neutropenia (eight patients, 13 cycles) and diarrhoea (nine
patients, 11 cycles). Meanwhile, the capecitabine doses were
modified mainly owing to neutropenia, diarrhoea, or HFS. The
mean dose intensity over all the treatment cycles was
8641mgm
 2week
 1 for capecitabine and 58.4mgm
 2week
 1 for
irinotecan, corresponding to 92.6 and 87.6% of the planned dose
intensity, respectively. The compliance with capecitabine was
96.0% for all the treatment cycles.
DISCUSSION
In the current study, the combination chemotherapy of capecita-
bine and irinotecan, which can be administered on an outpatient
basis, produced active antitumour activity and a safe toxicity
profile in patients with advanced gastric cancer. The overall
response rate (46.3%), median TTP (5.1 months), and median
overall survival (8.6 months) following treatment with the present
regimen were comparable with previous results reported for
cisplatin-based combinations (Kim et al, 1993; Boku et al, 1999;
Roth et al, 2000; Vanhoefer et al, 2001), where a continuous
infusion of a 5-FU and cisplatin regimen achieved a response rate
of 37–51% and median overall survival of 9–9.7 months (Kim
et al, 1993; Vanhoefer et al, 2001), whereas docetaxel or irinotecan
plus cisplatin regimens achieved a response rate and median
overall survival of 48–56% and 9–9.06 months, respectively (Boku
et al, 1999; Roth et al, 2000).
Recently, in meta-analysis for advanced gastric cancer (Wagner
et al, 2005), combination chemotherapy improved survival
compared to single-agent 5-FU, and best survival results were
achieved with regimens containing 5-FU, anthracycline, and
cisplatin among the various combination chemotherapies. How-
ever, Dank et al (2005) reported that irinotecan plus 5-FU/folinic
acid showed a trend to TTP superiority, compared with cisplatin
and 5-FU, as well as a better safety profile in a randomised phase
III trial. And they suggested that irinotecan plus 5-FU/folinic acid
Table 1 Patient characteristics
Characteristic
Number of
patients (N¼41, %)
Age (years)
Median 59
Range 25–74
Gender
Male 30 (73.2)
Female 11 (26.8)
ECOG performance status
0 1 (2.4)
1 37 (90.2)
2 3 (7.3)
Disease status
Metastatic 29 (70.7)
Recurrent 12 (29.3)
Location of primary tumour
Upper 8 (19.5)
Middle 11 (26.8)
Lower 22 (53.7)
Histology
Adenocarcinoma, well differentiated 3 (7.3)
Adenocarcinoma, moderately differentiated 13 (31.7)
Adenocarcinoma, poorly differentiated 25 (61.0)
Metastatic sites
Liver 21 (32.8)
Peritoneum 10 (15.6)
Distal lymph nodes 22 (34.4)
Ovary 6 (9.4)
Others (lung, bone, uterus, and spleen) 5 (7.8)
Number of metastatic sites
1 21 (51.2)
2 19 (46.3)
X3 1 (2.4)
Table 2 Tumour response (intention-to-treat analysis)
Response Number (n¼41, %)
Confirmed response 19 (46.3)
a
Complete response 3 (7.3)
Partial response 16 (39.0)
Stable disease 6 (14.6)
Progressive disease 13 (31.7)
Not assessable 3 (7.3)
a95% CI¼30.4–62.3%.
1.0
0.8
0.6
0.4
0.2 Time to progression
Overall survival
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0
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Figure 1 Kaplan–Meier curves for time to disease progression and
overall survival for intention-to-treat population (n¼41).
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for patients with advanced gastric cancer.
Capecitabine has already been shown to be active and safe in
the treatment of previously untreated advanced gastric cancer. A
recent phase II study by Kim et al (2002) reported that a
capecitabine plus cisplatin regimen produced a high response rate
of 54.8% and median overall survival of 10.1 months in patients
with advanced gastric cancer. In contrast, the current study used
a reduced dose of capecitabine, 1000mgm
 2 instead of
1250mgm
 2, owing to the relatively high incidence of HFS. Grade
2/3 HFS has previously been observed in 27.5–50% of patients
with advanced gastric cancer who received the standard dose
of capecitabine (Kim et al, 2002; Park et al, 2004), and as there is
no effective prophylaxis or treatment for HFS, this can interrupt
treatment or reduce the dose intensity of capecitabine. In the
present trial, only four patients (10.0%) experienced grade 2 HFS,
allowing the dose intensity of capecitabine to reach 92.6%.
The major toxicities related to irinotecan are diarrhoea and
myelosuppression, which are known to be dose-dependent.
Chemotherapy-induced severe diarrhoea or neutropenia can also
result in treatment-related hospitalisation or mortality, thereby
compromising the quality of life and increasing medical expendi-
ture. Ajani et al (2002) reported that the weekly administration of
irinotecan (65mgm
 2) and cisplatin (30mgm
 2) for 4 consecutive
weeks followed by a 2-week break showed active antitumour
activity in patients with untreated, advanced adenocarcinoma of
the stomach or gastroesophageal junction. However, in their study,
27% of the patients experienced grade 3/4 neutropenia and 22%
experienced grade 3/4 diarrhoea. Thus, owing to the high
incidence of toxicities and treatment interruptions, they suggested
that modification of the doses and schedule might be warranted to
make the regimen more tolerable to patients. The combination
regimen of irinotecan (80mgm
 2) followed by folinic acid
(500mgm
 2) and 5-FU (2000mgm
 2 i.v. over 22h) weekly for 6
weeks also showed 25% of grade 3/4 neutropenia, 5% of febrile
neutropenia, and 22% of grade 3/4 diarrhoea in a randomised trial
(Dank et al, 2005).
Recently, in a randomised multicentre phase II trial (Bajetta
et al, 2004) comparing two different schedules of irinotecan
combined with capecitabine as the first-line treatment for
metastatic colorectal cancer, diarrhoea, which occurred in 37.8%
of the patients at a grade 3/4 intensity, was the main adverse effect
of the arm B regimen (capecitabine 1000mgm
 2 twice daily on
days 2–15 and irinotecan 120mgm
 2 on days 1 and 8, every 21
days). However, in the present study, a reduced dose of irinotecan
(100mgm
 2 on days 1 and 8) was administered to alleviate
adverse effects, and grade 3/4 diarrhoea and neutropenia was only
observed in 15 and 10% of the patients, respectively. Furthermore,
there was no treatment-related death or grade 4 non-haematolo-
gical adverse event.
In case of an irinotecan and 5-FU combination, the
schedule-dependent interactions with respect to toxicity have
already been demonstrated. Thus, a schedule of irinotecan
followed by 5-FU infusion was found to be less toxic than the
reversed schedule, and explained by a reduced SN-38 area under
the curve level when the irinotecan preceded the infusional 5-FU
(Falcone et al, 2001). Accordingly, in the present study, the
irinotecan infusion preceded the capecitabine medication. As such,
the better tolerability of the present regimen may have been
associated with the schedule-dependent interaction between
capecitabine and irinotecan.
In conclusion, the combination of capecitabine and irinotecan
was found to be well tolerated and effective in patients with
advanced gastric cancer. Accordingly, this regimen can be
regarded as one of first-line treatment options for advanced
gastric cancer.
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